Results 11 to 20 of about 1,341 (183)

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. [PDF]

Crit Care
Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with candidaemia ...
Honoré PM, Girardis M, Kollef M, Cornely OA, Thompson GR, Bassetti M, Soriano A, Huang H, Vazquez J, Kullberg BJ, Pappas PG, Manamley N, Sandison T, Pullman J, Nseir S.   +14 more
europepmc   +5 more sources

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins [PDF]

Journal of Fungi, 2020
Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Guillermo Garcia-Effron
doaj   +6 more sources

The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics. [PDF]

J Antimicrob Chemother
Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which may negatively impact their ...
Andes D, Brüggemann RJ, Flanagan S, Lepak AJ, Lewis RE, Ong V, Rubino CM, Sandison T.   +7 more
europepmc   +5 more sources

A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin

IDCases
Antifungal resistance in Candida glabrata can develop to different classes of drugs, including the azoles and echinocandins. This organism is known to cause infective endocarditis with a particular predilection for prosthetic valves.
Divya Chandramohan, Samantha Aguilar, Gerard Gawrys, Nathan P. Wiederhold, Kristi Traugott, Thomas F. Patterson   +5 more
doaj   +4 more sources

O04 Use of the novel antifungal rezafungin in outpatient parenteral antibiotic therapy: early experience from a single centre [PDF]

JAC Antimicrob Resist
Background Rezafungin is a novel long-acting echinocandin antifungal drug with weekly dosing, which was licensed for treatment of invasive candidiasis in the UK in January 2024.
H. Davidson, I. Dunstan, T. Yau, A. Houston, M. Basarab, T. Bicanic   +5 more
europepmc   +5 more sources

Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study. [PDF]

Clin Infect Dis
Background Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial (NCT03667690)
Soriano A, Honore PM, Cornely OA, Chayakulkeeree M, Bassetti M, Haihui H, Dupont H, Kim YK, Kollef M, Kullberg BJ, Manamley N, Pappas P, Pullman J, Sandison T, Dignani C, Vazquez JA, Thompson GR.   +16 more
europepmc   +9 more sources

New Perspectives on Antimicrobial Agents: Rezafungin. [PDF]

Antimicrob Agents Chemother
Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins.
Forrister NM, McCarty TP, Pappas PG.
europepmc   +4 more sources

Successful rezafungin treatment of an azole-resistant Candida parapsilosis vascular graft infection. [PDF]

Rev Esp Quimioter
,
Benítez-Cano A, Rivera L, Ramos I, Carazo J, Carrillo-Villamizar E, Luque S, Adalia R, Sorlí L.   +7 more
europepmc   +4 more sources

The In Vitro Activity of Rezafungin Against Uncommon Species of Candida

Mycoses, Volume 67, Issue 11, November 2024.
Invasive candidiasis (IC) is increasing due to the rising numbers of immunocompromised patients. Increasing azole resistance rates and daily dosing required for most echinocandins have complicated its treatment. The approval of rezafungin has provided an
Marisa L. Winkler, P. Rhomberg, Abby L. Klauer, Samuel Edeker, M. Castanheira   +4 more
semanticscholar   +4 more sources

Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program

Microorganisms
Candida spp. spondylodiscitis is a rare condition for which treatment options are often limited. A further obstacle is the duration of therapy, which should be administered for up to twelve months.
Giulio Viceconte, Antonio Riccardo Buonomo, Nunzia Esposito, Letizia Cattaneo, Teresa Somma, Maria Michela Scirocco, Ciro Gabriele Mainolfi, Ivan Gentile   +7 more
doaj   +5 more sources